Ramatroban
Suppliers
Names
[ CAS No. ]:
116649-85-5
[ Name ]:
Ramatroban
[Synonym ]:
MFCD00887606
9H-Carbazole-9-propanoic acid, 3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-, (3R)-
3-[(3R)-3-{[(4-Fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl]propanoic acid
BAY u 3405
(+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid
Baynas
3-((3R)-3-(((4-Fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic Acid
BAY u-3405
Ramatroban
3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
Chemical & Physical Properties
[ Density]:
1.4±0.1 g/cm3
[ Boiling Point ]:
654.7±65.0 °C at 760 mmHg
[ Molecular Formula ]:
C21H21FN2O4S
[ Molecular Weight ]:
416.466
[ Flash Point ]:
349.7±34.3 °C
[ Exact Mass ]:
416.120605
[ PSA ]:
96.78000
[ LogP ]:
4.09
[ Vapour Pressure ]:
0.0±2.1 mmHg at 25°C
[ Index of Refraction ]:
1.664
[ Storage condition ]:
Desiccate at -20°C
MSDS
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H315-H319-H335
[ Precautionary Statements ]:
P261-P305 + P351 + P338
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xi
[ Risk Phrases ]:
36/37/38
[ Safety Phrases ]:
26-36/37/39-45
[ RIDADR ]:
NONH for all modes of transport
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Eur. J. Pharmacol. 554(2-3) , 229-34, (2007)
This study was undertaken to investigate the interactive effect of histamine and prostaglandin D(2) in nasal allergic symptoms in rats. The intranasal application of histamine at doses lower than 10 m...
Int. Arch. Allergy Immunol. 149(4) , 315-22, (2009)
Interleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis. Histamine and prostaglandin D(2) are importan...
Auris. Nasus. Larynx. 33(4) , 455-60, (2006)
The pathogenesis of eosinophilic otitis media is not yet fully understood. The purpose of this paper is to describe the clinical course of our two patients with eosinophilic otitis media and to discus...